Log in

Basilea Pharmaceutica Stock Forecast, Price & News

0.00 (0.00 %)
(As of 12/3/2020 12:00 AM ET)
Today's Range
Now: $59.30
50-Day Range
MA: $55.03
52-Week Range
Now: $59.30
Average Volume16 shs
Market Capitalization$636.88 million
P/E RatioN/A
Dividend YieldN/A
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, as well as Ceftobiprole, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor. The company was founded in 2000 and is headquartered in Basel, Switzerland.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.57 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$135.28 million
Book Value($7.88) per share



Market Cap$636.88 million
Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPMUF News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Basilea Pharmaceutica (OTCMKTS:BPMUF) Frequently Asked Questions

How has Basilea Pharmaceutica's stock been impacted by Coronavirus (COVID-19)?

Basilea Pharmaceutica's stock was trading at $44.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BPMUF stock has increased by 33.9% and is now trading at $59.30.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Basilea Pharmaceutica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Basilea Pharmaceutica
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Basilea Pharmaceutica?

Wall Street analysts have given Basilea Pharmaceutica a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Basilea Pharmaceutica wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Basilea Pharmaceutica?

Basilea Pharmaceutica saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 566,000 shares, an increase of 13.8% from the October 15th total of 497,200 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 5,660.0 days.
View Basilea Pharmaceutica's Short Interest

Who are some of Basilea Pharmaceutica's key competitors?

Who are Basilea Pharmaceutica's key executives?

Basilea Pharmaceutica's management team includes the following people:
  • Mr. David Veitch, Chief Exec. Officer (Age 55)
  • Mr. Adesh Kaul, Chief Financial Officer (Age 46)
  • Dr. Gerrit Hauck, Chief Technology Officer (Age 56)
  • Dr. Laurenz Kellenberger, Chief Scientific Officer (Age 53)
  • Dr. Marc Engelhardt, Chief Medical Officer (Age 56)
  • Dr. Peer Nils Schröder, Head of Corp. Communications & Investor Relations
  • Mr. Damian Heller, Gen. Counsel & Corp. Sec. (Age 54)
  • Ms. Ursula Eberhardt, Head of Global HR (Age 58)
  • Mr. Lutz Wevelsiep, Head of Regulatory Affairs
  • Mr. Dietrich Stüber, Head of Internal Services

What is Basilea Pharmaceutica's stock symbol?

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Basilea Pharmaceutica's stock price today?

One share of BPMUF stock can currently be purchased for approximately $59.30.

How big of a company is Basilea Pharmaceutica?

Basilea Pharmaceutica has a market capitalization of $636.88 million and generates $135.28 million in revenue each year. The company earns $-22,490,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Basilea Pharmaceutica employs 225 workers across the globe.

What is Basilea Pharmaceutica's official website?

The official website for Basilea Pharmaceutica is www.basilea.com.

How can I contact Basilea Pharmaceutica?

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company can be reached via phone at 41-61-606-1111 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.